Cos (e.g., Cos-7, Etc.) Patents (Class 435/365)
Expressing recombinant lymphokine, interferon, hormone, growth factor or morphogen (Class 435/365.1)
-
Publication number: 20130017597Abstract: Use of a biological photoreceptor as light-controlled ion channel for the alteration of the ion conductivity of a membrane by means of light. The photoreceptor used comprises an apoprotein and a light-sensitive polyene covalently bound to the apoprotein, said polyene interacting with the apoprotein and functioning as a light-sensitive gate.Type: ApplicationFiled: April 23, 2012Publication date: January 17, 2013Applicant: MAX-PLANCK-GESEL. ZUR FOERDERUNG DER WISSEN. EV.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Publication number: 20130011919Abstract: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.Type: ApplicationFiled: June 17, 2010Publication date: January 10, 2013Inventor: Alexey Ryazanov
-
Publication number: 20130011375Abstract: The present invention relates generally to the field of immunology. More particularly, aspects of the invention concern the discovery of several T cell receptors (TCRs) that are specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, methods of making TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) proliferation.Type: ApplicationFiled: November 23, 2010Publication date: January 10, 2013Applicant: CHRONTECH PHARMA ABInventor: Margaret Sällberg Chen
-
Publication number: 20130011426Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.Type: ApplicationFiled: May 15, 2012Publication date: January 10, 2013Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
-
Publication number: 20130004543Abstract: Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, or KGF and fibronectin, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of fibronectin. These protein complexes include synthetic proteins where the growth factor and fibronectin sequences are joined by a linker sequence. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.Type: ApplicationFiled: November 30, 2010Publication date: January 3, 2013Applicant: Queensland University of TechnologyInventors: Zee Upton, Derek Van Lonkhuyzen
-
Publication number: 20130004416Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: August 31, 2012Publication date: January 3, 2013Applicant: Abbott LaboratoriesInventors: Chengbin WU, Tariq Ghayur, Richard W. Dixon, Jochen G. Salfeld
-
Publication number: 20130004471Abstract: The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.Type: ApplicationFiled: June 8, 2012Publication date: January 3, 2013Applicant: BLUEBIRD BIO, INC.Inventors: Maria Joann Denaro, Mitchell Howard Finer, Gabor Veres
-
Publication number: 20130004490Abstract: The invention provides a composition comprising transthyretin and an ICAM-1 targeting agent, wherein the transthyretin and ICAM-1 targeting agent are coupled together, as well as methods of preparing such compositions. The invention further provides a diabody capable of binding specifically to ICAM-1 and transthyretin. The invention also provides a method of use of such composition in the manufacture of a medicament for treating an amyloid-? related neurodegenerative disease, comprising administering to a subject a composition comprising transthyretin coupled to an ICAM-1 targeting agent in an amount effective to treat the neurodegenerative disease, wherein the composition is administered to the subject outside of the blood-brain barrier.Type: ApplicationFiled: December 14, 2010Publication date: January 3, 2013Applicants: UNIVERSITY OF MARYLAND, COLLGE PARK, of Health and Human ServicesInventors: Juan Jose Marugan, Wei Zheng, Silvia Muro-Galindo
-
Publication number: 20120329150Abstract: The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: MedImmune, LLCInventors: Gregory Duke, George Kemble, James Young, Zhaoti Wang
-
Publication number: 20120322147Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.Type: ApplicationFiled: November 10, 2010Publication date: December 20, 2012Applicant: INSERM(institut National de la Sante et de la Recherche Medicale)Inventors: Philippe Mangeot, Vincent Lotteau
-
Publication number: 20120321626Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.Type: ApplicationFiled: May 16, 2012Publication date: December 20, 2012Applicant: FABION PHARMACEUTICALS, INC.Inventor: Hongxing Zhou
-
Publication number: 20120322149Abstract: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-?36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.Type: ApplicationFiled: August 7, 2012Publication date: December 20, 2012Applicant: CREIGHTON UNIVERSITYInventor: Zhao Yi Wang
-
Publication number: 20120315256Abstract: The invention refers to the use of transforming growth factor-beta 1 (TGF-?1) inhibitor peptides or polynucleotides encoding said peptides for the prevention and/or treatment of corneal fibrosis and/or corneal haze.Type: ApplicationFiled: February 21, 2011Publication date: December 13, 2012Applicants: DIGNA BIOTECH, S.I., PROYECTO DE BIOMEDICINA CIMA S.L.Inventors: Javier Dotor De Las Herrerias, Miguel Jose Maldonado Lopez
-
Publication number: 20120317664Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.Type: ApplicationFiled: May 31, 2012Publication date: December 13, 2012Applicant: CELLECTIS S.A.Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frédéric Paques
-
Patent number: 8329420Abstract: The present invention provides a method of screening for a drug for the prophylaxis or treatment of at least one disease selected from the group consisting of cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, severe sepsis and septic shock, which includes selecting a substance that binds to an intracellular region of TLR4, and inhibits signal transduction from said molecule, and a kit for this method, which contains (1) a cell that expresses wild-type TLR4 and (2) a cell that expresses a mutant TLR4, and which can detect a signal from TLR4 with expression of a reporter gene as an index.Type: GrantFiled: March 29, 2007Date of Patent: December 11, 2012Assignees: Hiroshima University, Takeda Pharmaceutical Company LimitedInventors: Osamu Hazeki, Kaoru Hazeki, Masayuki Ii, Naoko Matsunaga
-
Publication number: 20120308591Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.Type: ApplicationFiled: December 13, 2010Publication date: December 6, 2012Applicant: Onco Therapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20120309050Abstract: An object of the present invention is to provide a method for increasing the expression of foreign genes, in particular, using a promoter, an enhancer, and the like, and an expression cassette containing a promoter, an enhancer, and the like, by which gene expression can be increased. The purpose is achieved with the use of the gene expression cassette comprising a DNA construct containing a gene to be expressed and a poly A addition sequence that are located downstream of a 1st promoter, and further comprising an enhancer or a 2nd promoter ligated downstream of the DNA construct.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Inventors: Hiromi Kumon, Nam-Ho Huh, Masakiyo Sakaguchi, Masami Watanabe
-
Patent number: 8324362Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.Type: GrantFiled: May 26, 2010Date of Patent: December 4, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
-
Publication number: 20120301919Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.Type: ApplicationFiled: May 24, 2012Publication date: November 29, 2012Applicant: Agency for Science, Technology and ResearchInventors: Yuansheng Yang, Steven Ho, Jia Juan Lee
-
Publication number: 20120304321Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.Type: ApplicationFiled: May 31, 2012Publication date: November 29, 2012Applicant: CELLECTIS S.A.Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frédéric Paques
-
Publication number: 20120301493Abstract: The invention is based on the identification of the minimum region of the avian Orthoreovirus muNS protein which is capable of forming inclusions as well as on the identification of specific regions of the muNS protein showing capacity to associate with the inclusions formed by muNS. The identification of said regions allows developing methods for purifying recombinant polypeptides as well as methods for detecting the interaction between two polypeptides of interest.Type: ApplicationFiled: February 11, 2011Publication date: November 29, 2012Inventors: Alberto Brandariz Nunez, Rebeca Menaya Vargas, Francisco Javier Benavente Martinez, Jose Manuel Martinez Costas
-
Publication number: 20120301497Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: ApplicationFiled: August 3, 2012Publication date: November 29, 2012Inventors: Anjali Yadava, Christian F. Ockenhouse
-
Publication number: 20120294796Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.Type: ApplicationFiled: May 4, 2012Publication date: November 22, 2012Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Z. Chen
-
Publication number: 20120295326Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: ApplicationFiled: July 31, 2012Publication date: November 22, 2012Applicants: The Board of Trustees of the Leland Stanford Junior University, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Publication number: 20120288883Abstract: This invention relates to a probe reagent comprising, in order from the N-terminus to the C-terminus, the amino acid sequences of a fluorescent protein I, a peptide capable of terminating protein degradation (i.e., a degradation-terminating peptide), a spacer peptide, a fluorescent protein II, and a protein to be degraded, wherein the protein to be degraded is a protein degraded by the ubiquitin-proteasome system, and the probe reagent is degraded from the C-terminus, but that the degradation of the probe reagent is terminated at the degradation-terminating peptide, a nucleic acid encoding the probe reagent, and use of the probe reagent or the nucleic acid.Type: ApplicationFiled: January 21, 2011Publication date: November 15, 2012Inventors: Atsushi Miyawaki, Masahiko Hirano
-
Publication number: 20120289468Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.Type: ApplicationFiled: November 12, 2010Publication date: November 15, 2012Applicant: GRIFOLS THERAPEUTICS INC.Inventor: Thomas Barnett
-
Publication number: 20120282285Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to anti-bodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: ApplicationFiled: July 16, 2010Publication date: November 8, 2012Applicants: RIGSHOSPITALET, SYDDANSK UNIVERSITET, KØBENHAVNS UNIVERSITETInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20120283120Abstract: The present invention provides a novel variant androgen receptor (ARaiv) lacking ligand binding domain, a nucleic acid encoding the same and use thereof. That is, the present invention provides a method of screening for a substance for the prophylaxis or treatment of cancer, which includes contacting an ARaiv protein or ARaiv-producing cell with a test compound, measuring the activity of ARaiv (e.g., transcription regulating action of androgen responsive gene) or expression level thereof, and selecting a compound that suppresses the activity or expression level.Type: ApplicationFiled: September 28, 2010Publication date: November 8, 2012Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuya Watanabe, Kazuhide Nakayama, Daisuke Nakata, Masami Kusaka
-
Publication number: 20120282290Abstract: There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.Type: ApplicationFiled: October 15, 2010Publication date: November 8, 2012Applicants: IMAXIO SA, ISIS INNOVATION LIMITEDInventors: Alexandra Jane Spencer, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Fergal Hill
-
Publication number: 20120282271Abstract: The invention provides methods and compositions for modulating hepsin activity and the MSP/Ron pathway, in particular by regulating pro-MSP activation by hepsin.Type: ApplicationFiled: October 21, 2010Publication date: November 8, 2012Applicant: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer
-
Publication number: 20120283408Abstract: A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.Type: ApplicationFiled: August 6, 2010Publication date: November 8, 2012Applicant: SAMSUNG ELECTRONIC CO., LTD.Inventors: Jae-Il Lee, Young-Sun Lee, Tae-Soo Lee
-
Publication number: 20120282177Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer.Type: ApplicationFiled: November 2, 2010Publication date: November 8, 2012Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120283314Abstract: The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.Type: ApplicationFiled: July 25, 2012Publication date: November 8, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Kenneth John McCormack, Christopher Dinesh Raj
-
Publication number: 20120277410Abstract: Fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related compositions and methods for recombinant protein production are provided, wherein the fusion polypeptides comprise a sequence derived from a plant dehydrin protein covalently linked to a heterologous protein sequence in order to enhance the solubility and folding of the heterologous protein sequence and to reduce its aggregation.Type: ApplicationFiled: March 30, 2012Publication date: November 1, 2012Applicant: MOLECULAR KINETICS INCORPORATEDInventors: Alan Keith Dunker, Aaron Andrew Santner, Vladimir N. Uversky
-
Publication number: 20120276611Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided.Type: ApplicationFiled: May 3, 2012Publication date: November 1, 2012Inventor: Valery Novokhatny
-
Publication number: 20120277143Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.Type: ApplicationFiled: April 27, 2012Publication date: November 1, 2012Inventors: Steven Jacobs, Karyn O'Neil, Michael Baumann, Gaby Sennhauser
-
Publication number: 20120276078Abstract: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.Type: ApplicationFiled: July 13, 2012Publication date: November 1, 2012Applicant: BP Corporation North America Inc.Inventors: Edward J. Bylina, Ronald Swanson, Eric Mathur, David E. Lam
-
Publication number: 20120276147Abstract: The invention relates to CTSP polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, CTSP-1.Type: ApplicationFiled: May 2, 2012Publication date: November 1, 2012Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Raphael Bessa PARMIGIANI, Maria Dulcetti Vibranovski, Sandro Jose de Souza, Anamaria Aranha Camargo
-
Publication number: 20120276548Abstract: The technology relates in part to multimer conjugates comprising a scaffold linked to two or more polypeptides that specifically interact with a nucleic acid containing beta-D-glucosyl-hydroxymethylcytosine or beta-D-glucosyl-hydroxymethyluracil. The scaffold can be chosen from an antibody, an antibody fragment, a multimerized binding partner that interacts with a binding partner counterpart in each of the polypeptides, a polymer, and a polyfunctional molecule. The polypeptides can be from a kinetoplastid flagellate organism and may comprise a full-length native or modified protein or a fragment thereof that specifically interacts with the beta-D-glucosyl-hydroxymethylcytosine and/or the beta-D-glucosyl-hydroxymethyluracil in the nucleic acid. The conjugates provided herein can be used to detect the presence, absence or amount of beta-D-glucosyl-hydroxymethylcytosine and/or beta-D-glucosyl-hydroxymethyluracil-containing nucleic acid in a sample.Type: ApplicationFiled: April 25, 2012Publication date: November 1, 2012Applicant: SEQUENOM, INC.Inventor: Karsten Schmidt
-
Publication number: 20120270230Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: June 11, 2012Publication date: October 25, 2012Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Wame, Malcolm Peter Weir
-
Publication number: 20120269788Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: March 7, 2012Publication date: October 25, 2012Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Publication number: 20120269840Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.Type: ApplicationFiled: April 27, 2012Publication date: October 25, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.Inventors: Susan W. BARNETT, Jan ZUR MEGEDE, Indresh SRIVASTAVA, Ying LIAN, Karin HARTOG, Hong LIU, Catherine GREER, Mark SELBY, Christopher WALKER
-
Publication number: 20120269851Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: ApplicationFiled: February 17, 2012Publication date: October 25, 2012Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
-
Publication number: 20120269798Abstract: The invention provides compositions and methods of use for identifying modulators of NOTUM, e.g., NOTUM inhibitors. In some aspects, identified compounds are useful for modulating Wnt signaling at sites of tissue damage. The invention further provides methods of promoting regeneration by inhibiting NOTUM.Type: ApplicationFiled: March 22, 2012Publication date: October 25, 2012Inventors: Peter Reddien, Christian Petersen
-
Publication number: 20120264168Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: February 27, 2012Publication date: October 18, 2012Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Publication number: 20120263724Abstract: Immunogenic Escherichia coli O157:H7 (0157) proteins expressed during infection of a mammal, are described. In particular, 0157 proteins expressed specifically in vivo during human and cattle infection were identified. These proteins, mapped to the backbone, O-islands (OIs) and pO157. Because these-proteins are expressed during infection, and might help pathogens adapt to and counter hostile in vivo environments, those proteins identified in this study are useful as targets for drug and vaccine development. Also, such proteins are useful as markers of 0157 infection in stool specimens. Also described are methods of identifying immunogenic proteins.Type: ApplicationFiled: April 20, 2006Publication date: October 18, 2012Inventors: Manohar John, Indira T. Kudva, Stephen B. Calderwood, Bryan Krastins, David A. Sarracino
-
Publication number: 20120251514Abstract: The invention provides nucleic acids comprising a nucleotide sequence encoding programmed death ligand-1 (PD-L1) and a nucleotide sequence encoding a fusion protein comprising thymidylate kinase (TMPK) or a variant thereof and a cell surface marker or a variant thereof. Recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and kits relating to the nucleic acids are disclosed. Methods of treating or preventing a disease in a host and methods of suppressing an immune system in a host are also disclosed.Type: ApplicationFiled: November 12, 2010Publication date: October 4, 2012Applicants: University Health Network, The United States of America, as rep. by the Sec. Department of Health and Human ServicesInventors: Daniel Fowler, Shoba Amarnath, Jeffrey Medin, James Chian Ming Wang
-
Publication number: 20120252699Abstract: The present invention relates to novel fluorophores and their use in combination with novel nucleic acid molecules, called aptamers, that bind specifically to the fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described.Type: ApplicationFiled: February 18, 2010Publication date: October 4, 2012Applicant: CORNELL UNIVERSITYInventors: Samie R. Jaffrey, Jeremy S. Paige
-
Publication number: 20120253088Abstract: Compositions and methods for producing olefins are described herein. The olefins can be used to produced biofuels.Type: ApplicationFiled: April 20, 2012Publication date: October 4, 2012Applicant: LS9, INC.Inventors: MURTAZA F. ALIBHAI, MATHEW A. RUDE, ANDREAS W. SCHIRMER
-
Publication number: 20120252097Abstract: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.Type: ApplicationFiled: October 25, 2011Publication date: October 4, 2012Inventors: Michael G. Rosenblum, Yuying Liu